Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin's lymphoma.
Journal: Journal Of Oncology Pharmacy Practice : Official Publication Of The International Society Of Oncology Pharmacy Practitioners
Published:
Abstract
Posterior reversible encephalopathy syndrome (PRES) is characterized by a group of central nervous system related symptoms. Diagnosis is usually made by computed tomography or magnetic resonance imaging. Common causes can be arterial hypertension, sepsis, autoimmune disorders, and medications. We report PRES in a relapsed Hodgkin's Lymphoma patient after a dose of pembrolizumab.
Authors
Justin Laporte, Melhem Solh, Serge Ouanounou
Relevant Conditions